Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eylea
Pharma
Asian patients with PCV show improvement with Roche's Vabysmo
Interim results from a trial of Roche's Vabysmo on Asian patients with polypoidal choroidal vasculopathy suggest that the treatment is effective.
Kevin Dunleavy
Nov 22, 2024 7:00am
Eylea HD sales jump in Q3 but Regeneron still cedes market share
Oct 31, 2024 11:37am
EyePoint's Duravyu bounces back with promising DME data
Oct 28, 2024 1:11pm
Roche's Vabysmo will rise above Eylea biosim threat, exec says
Oct 23, 2024 11:24am
Amgen gears up to launch Eylea biosim as Regeneron plots appeal
Oct 23, 2024 10:16am
Clearside's CLS-AX excels in phase 2b trial, set for phase 3
Oct 9, 2024 11:47am
